A new analysis of results from the SPRINT trial finds that across age groups, intensive blood pressure control may lengthen a person’s remaining lifespan by 4% to 9%.
A novel report on US opioid misuse melds results from a Harris Poll of 500 primary care physicians with Quest Diagnostics data on 4.4 million drug monitoring tests.
We preview findings of 2 studies on negative CV effects of e-cigarettes--on metabolic profiles and coronary blood flow--to be presented at the AHA 2019 Scientific Sessions next week.
The American College of Physicians today issued a guidance statement for routine colorectal cancer screening for average-risk adults.
The worst state for drug sales on school grounds? The best state for detox and rehab facilities? Test your best guess with these and 6 more best/worst comparisons.
Screening for depression among ACS patients is widely recommended by professional guidelines, but a new study suggests little return on the investment.
The SGLT2 inhibitor, on October 21, 2019 was granted a label expansion from FDA for the prevention of hospitalization for heart failure in patients with T2D.
Lasmitidan is the first 5-HT1F receptor agonist to receive FDA approval and was found superior to placebo for reduction of migraine pain and most bothersome symptom at 2 hours.
Motivational interviewing uses the common human problem of ambivalence about change to help clients shape their own solutions.
For people with type 2 diabetes, receiving motivational messages via mobile text was associated with reduced A1c vs patients who received usual care.